SCHEDULE: Cormorant Asset Management Discloses 6.7% Stake in Rapport
Beneficial Ownership Report
Cormorant Asset Management, LP and Bihua Chen reported a 6.7% beneficial ownership stake in Rapport Therapeutics, Inc. as of September 30, 2025.
Summary
- Cormorant Asset Management, LP and Bihua Chen collectively reported beneficial ownership of 3,192,521 shares of Rapport Therapeutics, Inc. Common Stock.
- This ownership represents 6.70% of the outstanding Common Stock of Rapport Therapeutics, Inc.
- The shares are held with shared voting power and shared dispositive power.
- The percentage of class is calculated based on 47,661,138 shares outstanding as of November 3, 2025, as reported in Rapport Therapeutics' Quarterly Report on Form 10-Q for the period ended September 30, 2025.
- The filing was made under Rule 13d-1(b), indicating the securities were acquired and are held in the ordinary course of business, not for influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine beneficial ownership disclosure (Schedule 13G) and does not inherently convey positive or negative sentiment about the company's operational or financial performance. It simply reports a significant stake held by an investment firm.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future performance or strategy.
Industry Context
This Schedule 13G filing indicates a significant institutional investment in Rapport Therapeutics, a common occurrence in the biotechnology and pharmaceutical sectors where specialized funds like Cormorant Asset Management often take positions in emerging or growth-stage companies. Such filings provide transparency into major shareholder positions, which can be a signal of investor confidence or strategic interest in the company's pipeline or market potential.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
- Management: Awareness of a major shareholder's position, though this filing indicates a passive investment without intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement (end of the reporting period for beneficial ownership). |
| 11/03/2025 | Date as of which 47,661,138 shares of Common Stock were outstanding, as reported by the Issuer. |
| 11/06/2025 | Date Rapport Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025. |
| 11/14/2025 | Date the Schedule 13G/A Amendment No. 2 was signed and filed. |
Keywords
Rapport Therapeutics, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Institutional Investor, Biotechnology, Healthcare, Investment, SEC Filing, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.